Will these bold bets pay off for Neil Woodford?

Roland Head takes a look at two of Neil Woodford’s top growth stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Star fund manager Neil Woodford is known for his big and successful bets on FTSE 100 stocks such as British American Tobacco and AstraZeneca. But he’s also a big fan of smaller, more speculative firms.

Today I’m going to take a look at two smaller stocks which have each grown to become top 20 holdings in Mr Woodford’s flagship Equity Income Fund. In both cases, Woodford Funds is also the largest institutional shareholder in each firm.

Too clever by half?

Mr Woodford is known for investing in small pharmaceutical, biotech and technology stocks. His team is able to research these fairly effectively in the UK. However, the US market for such firms is many times larger. That may be one reason why he has invested heavily in portfolio firm Allied Minds (LSE: ALM).

This firm invests in life science and technology start-ups in North America, with the aim of turning academic discoveries into commercial products. Investors in the company hope that this portfolio approach — combined with skilled research — will result in Allied striking gold.

The payback for this patient approach is the potential for a one-off windfall or lucrative long-term licensing revenues, such as from a new medicine. The risk, of course, is that this may never happen.

So far, Allied hasn’t managed to generate any cash for shareholders. The company has no revenue and is expected to report a loss of $88.7m for 2016.

One sign of hope is that the group’s founder and CEO, Chris Silva, has recently stepped down. He’s been replaced by Jill Smith whose appointment is intended to “accelerate commercial development across the portfolio.”

Ms Smith may succeed, but Allied remains highly speculative. If you’re tempted to follow Mr Woodford’s lead, it’s worth remembering that this stock only accounts for 1.83% of the Woodford Equity Income fund. I’d display similar caution if I was to invest myself.

This disruptive business could change everything

Woodford Funds is the largest shareholder of online estate agent Purplebricks Group (LSE: PURP). I’d imagine the holdings are now showing significant profits as Purplebricks’ stock has doubled in value over the last year.

There’s no doubt in my mind that the business model works and is gaining market share fast. Sales rose by 159% to £18.7m during the first half of the current year, while gross profit rose by 153% to £10.2m.

A UK gross profit margin of 55% suggests to me that the Purplebricks’ UK operations could soon start to generate meaningful profits. The risk is that the shares are already valued to reflect this growth potential.

A net loss of £9m is expected this year, as the firm continues to expand into new markets. But a profit of £1.14m is expected for 2017/18. That puts it on a forecast P/E of 165.

I’d normally run a mile from such an ambitious valuation. But Purplebricks is expanding fast and claims to have 67% of the UK online estate agency market. The group has also just raised £50m to fund a move into the much larger US market.

This stock could double or triple again. But it could also collapse. There’s no way to know. For me this is too speculative. But growth investors should probably continue to hold.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »